相关实验视频
Updated: Sep 20, 2025
06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
38.4K
cDC1s通过局部免疫促进动脉样硬化,并且可用于治疗
Miguel Galán1,2, Laura Fernández-Méndez3,4, Vanessa Núñez1
1Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (M.G., V.N., M.F.-M., P.F.-B., E.M.-R., S.M.-C., E.H.-G., M.R.-T., A.R.-R., C.R.-R., A.B., A.R.R., I.R.-V., D.S.).
Circulation research
|May 30, 2025
概括
传统的1型树突细胞 (cDC1s) 通过增强T细胞免疫力来促进动脉样硬化. 用甲装载纳米颗粒准cDC1s可以减少动脉样硬化病变而不会损害抗病毒反应,从而提供一种潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- 树突细胞生物学 树突细胞生物学
背景情况:
- 动脉样硬化涉及免疫细胞的积累和T助手1 (Th1) 免疫.
- 传统树突细胞 (cDCs) 在调节动脉样硬化中的适应性T细胞反应中的精确作用仍在争论中.
研究的目的:
- 研究cDCs在动脉样硬化发展中的作用.
- 确定cDC1s是否驱动适应性T细胞免疫力,从而导致动脉样硬化.
- 探索针对动脉样硬化的cDC1向免疫疗法.
主要方法:
- 使用高胆固醇饮食 (HCD) 的Ldlr-/-小鼠.
- 通过FLT3L过度表达和cDC1耗尽 (Xcr1Cre-DTA,Irf8Δ32模型) 操纵cDC群体.
- 使用流细胞计和单细胞RNA测序 (scRNA-seq) 分析T细胞子集.
- 开发并测试了针对抗CLEC9A的纳米颗粒,加载了用于免疫治疗的德克萨米他.
主要成果:
- cDC扩张加剧了动脉样硬化;cDC1枯竭阻止了它.
- 缺少cDC1会减少促炎性的CD4+ Th1和CD8+ IFN-γ+ T细胞.
- 在cDC1s中,STING通路对于它们的益风性功能至关重要.
- 向的纳米粒子减少了动脉样硬化病变和相关的T细胞反应,而不会影响抗病毒免疫力.
结论:
- 传统的1型树突细胞 (cDC1s) 通过促进CD4+和CD8+T细胞免疫力,起到益风性作用.
- 用免疫抑制纳米颗粒向cDC1s是一个潜在的策略,可以缓解动脉样硬化进展.
相关概念视频
01:30Coronary Artery Disease I: Introduction
69
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
69
01:26Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
01:30Atherosclerosis I: Introduction
97
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
97
01:38Inflammation
55.5K
Overview
55.5K
01:26Coronary Artery Disease II: Pathophysiology
44
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
44
01:26Coronary Artery Disease IV: Preventive Measures
40
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
40